Skip to main content
Premium Trial:

Request an Annual Quote

Osiris and Genetica Form Genomics Collaboration On Mesenchymal Cells

Premium

BALTIMORE--Osiris Therapeutics has entered into a research collaboration with Genetica, of Cold Spring Harbor, NY, that covers the functional genomics of human mesenchymal stem cells, the progenitors of structural and connective tissues. The collaboration will focus on the discovery of genes that control the growth and differentiation of the cells, to identify potential drug development targets. The companies said the venture takes advantage of Osiris's proprietary position in human mesenchymal stem cells and its expertise in cell and gene therapy, as well as of Genetica's novel genomics technology.

Osiris is engaged in research and development for therapeutic products for the regeneration of human structural and connective tissues through the use of the stem cells.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.